search icon
plyx-img

Polaryx therapeutics, inc. common stock share price

PLYX
NAQ
$2.33
-$0.1
(-4.12%)
1D
Industry: Biotechnology Sector: Health Care

Polaryx therapeutics, inc. common stock analyst forecast

Polaryx therapeutics, inc. common stock share price chart

Polaryx therapeutics, inc. common stock key stock metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$0
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
130.48K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.01 L
$48.91 H
$2.33

About polaryx therapeutics, inc. common stock, common stock

Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey. more

Industry: BiotechnologySector: Health Care

Polaryx therapeutics, inc. common stock stock returns

Time FramePLYXSectorS&P500
1-Week Return-12.08%0.13%0.01%
1-Month Return3.1%6.1%3.54%
3-Month Return-58.98%10.09%10.58%
6-Month Return-73.61%3.04%8.03%

Polaryx therapeutics, inc. common stock financials

Dec '23Dec '24Dec '25
Total Revenue---[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Cost of Revenue---[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Gross Profit---[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Gross Margin---[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Operating Expenses3.78M4.35M7.82M[{"date":"2023-12-31","value":48.34,"profit":true},{"date":"2024-12-31","value":55.65,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Operating Income(3.78M)(4.35M)(7.82M)[{"date":"2023-12-31","value":-378100000,"profit":false},{"date":"2024-12-31","value":-435200000,"profit":false},{"date":"2025-12-31","value":-782100000,"profit":false}]
Total Non-Operating Income/Expense---[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Pre-Tax Income(3.78M)(30.36M)(8.98M)[{"date":"2023-12-31","value":-377900000,"profit":false},{"date":"2024-12-31","value":-3035600000,"profit":false},{"date":"2025-12-31","value":-898500000,"profit":false}]
Income Taxes---[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income After Taxes---[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations(3.78M)(30.36M)(8.98M)[{"date":"2023-12-31","value":-377900000,"profit":false},{"date":"2024-12-31","value":-3035600000,"profit":false},{"date":"2025-12-31","value":-898500000,"profit":false}]
Income From Discontinued Operations---[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(3.78M)(30.36M)(8.98M)[{"date":"2023-12-31","value":-377900000,"profit":false},{"date":"2024-12-31","value":-3035600000,"profit":false},{"date":"2025-12-31","value":-898500000,"profit":false}]
EPS (Diluted)--(0.16)[{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":-16,"profit":false}]

Polaryx therapeutics, inc. common stock ratios

Polaryx therapeutics, inc. common stock liquidity ratios

These ratios help you determine the liquidity of the company. Higher is better.

PLYX
Cash Ratio 3.04
Current Ratio 3.45

Polaryx therapeutics, inc. common stock asset efficiency ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PLYX
ROA (LTM) -74.42%
ROE (LTM) -192.17%

Polaryx therapeutics, inc. common stock liability ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PLYX
Debt Ratio Lower is generally better. Negative is bad. 0.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.71

Polaryx therapeutics, inc. common stock valuation ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PLYX
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 46.48
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

Faqs

What is Polaryx Therapeutics, Inc. Common Stock share price today?

Polaryx Therapeutics, Inc. Common Stock (PLYX) share price today is $2.33

Can Indians buy Polaryx Therapeutics, Inc. Common Stock shares?

Yes, Indians can buy shares of Polaryx Therapeutics, Inc. Common Stock (PLYX) on Vested. To buy from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PLYX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Polaryx Therapeutics, Inc. Common Stock be purchased?

Yes, you can purchase fractional shares of Polaryx Therapeutics, Inc. Common Stock (PLYX) via the Vested app. You can start investing in Polaryx Therapeutics, Inc. Common Stock (PLYX) with a minimum investment of $1.

How to invest in Polaryx Therapeutics, Inc. Common Stock shares from India?

You can invest in shares of Polaryx Therapeutics, Inc. Common Stock (PLYX) via Vested in three simple steps:

  • Click on Sign Up or Invest in PLYX stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Polaryx Therapeutics, Inc. Common Stock shares

What is Polaryx Therapeutics, Inc. Common Stock 52-week high and low stock price?

The 52-week high price of Polaryx Therapeutics, Inc. Common Stock (PLYX) is $48.91. The 52-week low price of Polaryx Therapeutics, Inc. Common Stock (PLYX) is $2.01.

What is Polaryx Therapeutics, Inc. Common Stock price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Polaryx Therapeutics, Inc. Common Stock (PLYX) is

What is Polaryx Therapeutics, Inc. Common Stock price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Polaryx Therapeutics, Inc. Common Stock (PLYX) is 46.48

What is Polaryx Therapeutics, Inc. Common Stock dividend yield?

The dividend yield of Polaryx Therapeutics, Inc. Common Stock (PLYX) is 0.00%

What is the Market Cap of Polaryx Therapeutics, Inc. Common Stock?

The market capitalization of Polaryx Therapeutics, Inc. Common Stock (PLYX) is

What is Polaryx Therapeutics, Inc. Common Stock's stock symbol?

The stock symbol (or ticker) of Polaryx Therapeutics, Inc. Common Stock is PLYX

How Can Investors Use Polaryx Therapeutics, Inc. Common Stock Share Price Data for Long-Term Investment Decisions?

Consider the share price of Polaryx Therapeutics, Inc. Common Stock as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Polaryx Therapeutics, Inc. Common Stock has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Polaryx Therapeutics, Inc. Common Stock shares for Indian investors?

When investing in Polaryx Therapeutics, Inc. Common Stock shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Polaryx Therapeutics, Inc. Common Stock stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Polaryx Therapeutics, Inc. Common Stock share price with other stocks in the same sector?

Rather than merely checking the share price of Polaryx Therapeutics, Inc. Common Stock and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Polaryx Therapeutics, Inc. Common Stock stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top